Evaluation of Quality of Life and Disability in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Polyneuropathy Following Treatment with Patisiran, An Investigational RNAi Therapeutic: Results from the Phase 3 APOLLO Study (S31.003)
Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available
10.1212/wnl.90.15_supplement.s31.003